Global Diabetes Market; The

Therapeutics, Diagnostics and Complications

Publication Date	August 2006
Publisher	Arrowhead
Product Type	Report
Pages	218
ISBN Number	not applicable
Product Code	ARR00009

Price

£1,630.00
approximately: $2,501 | €1,917

PDF immediate delivery

Order above formats by FAX

Summary

Diabetes is one of the largest therapeutic segments of global pharmaceutical sales and during the last 10 years it has grown by a compound average growth rate of nearly 20% from around US$4 billion in 1995 to over US$17 billion in 2005. Overall, anti-diabetic drugs sales are expected to grow dramatically over the next five years to over US$22 billion in 2012 as the addressable patient population continues to increase and new, oral, injectable and pulmonary premium priced products enter the market to address high unmet clinical needs.

The Global Diabetes Market assesses the markets for diabetes therapeutics, as well as the markets for diagnostic products and those that treat diabetic complications. This new report from Arrowhead Publishers incorporates new clinical findings presented at the 2006 conference of the American Diabetes Association into our product outlooks and financial forecasts. This report also analyzes, clinically and financially, the leading products on the market, the major players, as well as the groundbreaking new products in clinical development. Financial forecasts are also provided for individual products as well as for product classes.

Key Features of This Report:

A thorough global market breakdown of key products and players in the non-insulin, insulin, diagnostic and diabetic neuropathy areas
Individual chapters outlining the drivers of and resistors on this growing market
Clinical evaluations of products and product classes in both the insulin and non-insulin markets
Financial forecasts through 2012 for products and product classes in the areas of insulin, non-insulin, alternative therapies and diabetic complications
Thorough analysis of products in clinical development, including coverage of safety, efficacy, market potential and filing timelines
96 tables/figures illustrating scientific and market aspects of the global diabetes market

Who Should Buy This Report:

Companies interested in understanding the wider opportunities and challenges in the markets for diabetes therapeutics, diagnostics and products for diabetic complications
Pharma/biotech companies wishing to identify opportunities and threats to products in these markets in order to examine a variety of profit maximization strategies
Companies interested in understanding the state of R&D in relation to insulin, non-insulin, diagnostics and diabetic complication products

Content

1 Summary
2 The Diabetes Market
- 2.1 Current Market Size
  - 2.1.1 The Insulin Market
  - 2.1.2 The Non-Insulin Market
  - 2.1.3 Sales of Diabetes Products Could Double by 2012
  - 2.1.4 The Diabetic Neuropathy Market
  - 2.1.5 The Glucose Monitoring Market
- 2.2 Key Players in the Diabetes Market - Winners & Losers
  - 2.2.1 Key Players in the Insulin Market
  - 2.2.2 The Key Players in the Non-Insulin Market
  - 2.2.3 The Key Players in the Treatment of Diabetic Neuropathy
  - 2.2.4 The Key Players in the Glucose Monitoring Market
  - 2.2.5 Major players in the Diabetes Market in 2012
3 The Facts about Diabetes
- 3.1 What is Diabetes?
  - 3.1.1 Type 1 Diabetes
  - 3.1.2 Type 2 Diabetes
- 3.2 How is it Diagnosed?
- 3.3 What are the Current Treatment Goals?
- 3.4 The Financial Burden of Diabetes
4 Patient Statistics
- 4.1 Type 1 Diabetes Statistics
- 4.2 Type 2 Diabetes Statistics
- 4.3 Type 2 Pre-Diabetes
- 4.4 Diabetes Complications
5 Market Drivers
- 5.1 Patient Dynamics
- 5.2 Improvements in Diagnosis
- 5.3 Improvements in Glucose Monitoring
- 5.4 Changes in Guidelines
- 5.5 Launch of New Treatments & Combinations
- 5.6 Increased Use of Pen Devices
- 5.7 Off-Label Use
6 Market Resistors
- 6.1 More Economic Use of Insulin
- 6.2 Patent Expiration
- 6.3 Drug Safety Issues
- 6.4 Health Insurance/Reimbursement
7 Non-Insulin Agents: Attributes, Efficacy & Financial Forecasts
- 7.1 Oral Anti-Diabetic Agents (OADs)
  - 7.1.1 Insulin Secretion Promoting Agents
    - 7.1.1.1 Sulfonylureas (SUs) are Cost Effective in Early Type 2 Diabetes
    - 7.1.1.1.1 Advantages and Disadvantages of Sus
    - 7.1.1.1.2 Sales Forecast of Leading SUs 2005A-2012E
    - 7.1.1.2 Meglitinides (MGs) Have Limited Uptake in the Market
    - 7.1.1.2.1 Advantages and Disadvantages of MGs
    - 7.1.1.2.2 Sales forecast of leading MGs 2005A-2010E
  - 7.1.2 Insulin Sensitizing Agents
    - 7.1.2.1 Biguanides (BGs) are First-Line Therapy for Obese Diabetics
    - 7.1.2.1.1 Advantages and Disadvantages of BGs
    - 7.1.2.1.2 Sales Forecasts of Leading BGs 2005A-2012E
    - 7.1.2.2 Thiazolidinediones (TZDs) Extensively Used in the Second-Line Setting
    - 7.1.2.2.1 Advantages and Disadvantages of TZDs
  - 7.1.3 Combination Therapy
    - 7.1.3.1 Advantages of Combination Therapies
    - 7.1.3.2 Sales Forecast of Leading TZD Therapies 2005A-2012E
  - 7.1.4 Glucose Absorption Inhibitors
    - 7.1.4.1 Alpha-GIs are First Line Treatment in Japan
    - 7.1.4.1.1 Advantages and Disadvantages of Alpha Gis
    - 7.1.4.1.2 Sales Forecasts of Leading Alpha GIs 2005A-2012E
- 7.2 Insulin Secretion Promoting Agents
  - 7.2.1 Byetta is the First in Class
    - 7.2.1.1 Advantages and Disadvantages of Byetta
    - 7.2.1.2 Sales Forecasts of Approved Insulin Secretion Promoting Agents 2005A-2012E
- 7.3 Amylinomimetic Agents
  - 7.3.1 Symlin is the First Approved Amylinomimetic
    - 7.3.1.1 Advantages and Disadvantages of Symlin
    - 7.3.1.2 Sales Forecasts of Approved Amylinomimetic Agents 2005A-2012E
- 7.4 Prescription Trends in the Non-Insulin Market
- 7.5 Sales Forecast for Approved Non-Insulin Agents 2005A-2012E
8 Insulin Agents
- 8.1 Injectable Insulin
  - 8.1.1 Short Acting Insulin versus Rapid Acting Analogues
    - 8.1.1.1 Advantages and Disadvantages of Rapid Acting Insulin
  - 8.1.2 Rapid-Acting Analogues
    - 8.1.2.1 Humalog (Eli Lilly)
    - 8.1.2.2 Novolog (Novo Nordisk)
    - 8.1.2.3 Apidra (Sanofi Aventis)
  - 8.1.3 Sales Forecast of Leading Short and Rapid Acting Insulin 2005A-2012E
  - 8.1.4 Intermediate Acting Insulin vs Long Acting Analogues
    - 8.1.4.1 Advantages and Disadvantages of Intermediate-Acting Insulin
    - 8.1.4.2 Humulin (Eli Lilly)
    - 8.1.4.3 Novolin (Novo Nordisk)
    - 8.1.4.4 Insuman (Sanofi-Aventis)
    - 8.1.4.5 Sales Forecast of Intermediate Insulin 2005A-2012E
  - 8.1.5 Pre-Mixes
    - 8.1.5.1 Sales Forecast of Insulin Mixes 2005A-2012E
  - 8.1.6 Long Acting Insulin Analogues
    - 8.1.6.1 Lantus (Sanofi Aventis)
    - 8.1.6.2 Levemir (Novo Nordisk)
    - 8.1.6.3 Sales Forecast of Leading Long-Acting Analogues 2005A-2012E
- 8.2 Pulmonary Insulin
  - 8.2.1 Exubera (Pfizer/Nektar)
    - 8.2.1.1 Exubera's Unique Pharmacokinetic Profile
    - 8.2.1.2 Advantages and Disadvantages of Exubera
    - 8.2.1.3 Exubera due for launch July 2006
  - 8.2.2 Sales Forecast of Pulmonary Insulin 2005A-2012E
- 8.3 Prescription Trends In The Insulin Market
- 8.4 Sales Forecast for Approved Insulin Agents 2005A-2012E
9 Future Treatments: Non-Insulin
- 9.1 More Efficacious Medicine
- 9.2 Safer Anti-Diabetic Agents
- 9.3 Insulin-Secretion Promoting Agents
  - 9.3.1 Advantages and Disadvantages of Insulin Secretion Promoting Agents
  - 9.3.2 New GLP-1 Analogues
    - 9.3.2.1 Liraglutide (Novo Nordisk)
    - 9.3.2.1.1 Efficacy
    - 9.3.2.1.2 Safety
    - 9.3.2.1.3 Development and Filing
    - 9.3.2.1.4 Forecasts
    - 9.3.2.2 AVE-OO10 (Sanofi Aventis)
    - 9.3.2.2.1 Efficacy
    - 9.3.2.2.2 Safety
    - 9.3.2.2.3 Development and Filing
    - 9.3.2.2.4 Forecasts
    - 9.3.2.3 Byetta LAR (Eli Lilly)
    - 9.3.2.3.1 Efficacy
    - 9.3.2.3.2 Safety
    - 9.3.2.3.3 Development and Filing
    - 9.3.2.3.4 Forecasts
  - 9.3.3 Other GLP-1 Analogues in Early Stage Clinical Development
    - 9.3.3.1 BIM 51077
    - 9.3.3.2 CS-872
    - 9.3.3.3 CJC-113
    - 9.3.3.4 GSK716155
  - 9.3.4 New DPP IV inhibitors
    - 9.3.4.1 Galvus (Novartis)
    - 9.3.4.1.1 Efficacy
    - 9.3.4.1.2 Safety
    - 9.3.4.1.3 Development and Filing
    - 9.3.4.1.4 Forecasts
    - 9.3.4.2 Januvia (Merck & Co.)
    - 9.3.4.2.1 Efficacy
    - 9.3.4.2.2 Safety
    - 9.3.4.2.3 Development and Filing
    - 9.3.4.2.4 Forecasts
    - 9.3.4.3 Saxagliptin (Bristol-Myers Squibb)
    - 9.3.4.3.1 Efficacy
    - 9.3.4.3.2 Safety
    - 9.3.4.3.3 Development and Filing
    - 9.3.4.3.4 Forecasts
  - 9.3.5 Other DPP IV Inhibitors in Clinical Development
    - 9.3.5.1 SYR322 (Takeda)
    - 9.3.5.2 Denaglipitin (GSK)
    - 9.3.5.3 PSN9301 (Prosidion)
    - 9.3.5.4 Sales Forecasts of New Insulin-Secretion Promoting Agents 2005A-2010E
  - 9.3.6 New Insulin Sensitizing Agents
    - 9.3.6.1 Advantages and Disadvantages of Dual Acting PPAR Agonists and PPAR Pan Agonists
  - 9.3.7 New Dual Acting PPAR Agonists
    - 9.3.7.1 Pargluva (Bristol-Myers Squibb)
    - 9.3.7.1.1 Efficacy
    - 9.3.7.1.2 Safety
    - 9.3.7.1.3 Development and Filing
    - 9.3.7.1.4 Forecasts
    - 9.3.7.2 Naveglitazar (Eli Lilly/Ligand)
    - 9.3.7.2.1 Efficacy
    - 9.3.7.2.2 Safety
    - 9.3.7.2.3 Development and Filing
    - 9.3.7.2.4 Forecasts
  - 9.3.8 Other dual acting PPAR agonists
    - 9.3.8.1 AVE-0847 (Sanofi Aventis)
    - 9.3.8.2 TAK-654 (Takeda)
    - 9.3.8.3 ONO-5129 (ONO Pharma)
  - 9.3.9 New PPAR Pan Agonists
    - 9.3.9.1 GW677954 (GSK)
    - 9.3.9.2 PLX204 (Plexxikon)
  - 9.3.10 New PPAR Gamma Agonists
    - 9.3.10.1 Rivoglitazone (Daiichi-Sankyo)
    - 9.3.10.2 Balaglitazone (Dr Reddy)
    - 9.3.10.3 CLX-0921 (Calyx Pharmaceuticals)
    - 9.3.10.4 Metaglidasen (Metabolex)
    - 9.3.10.5 AMG 131 (Amgen)
  - 9.3.11 New PPAR agonist combinations
  - 9.3.12 Sales Forecasts of New Insulin Sensitizing Agents 2005A-2012E
10 Future Treatments: Insulin
- 10.1 Pulmonary Insulin
  - 10.1.1 AERx iDMS (Novo Nordisk/Paradigm)
    - 10.1.1.1 Efficacy
    - 10.1.1.2 Safety
    - 10.1.1.3 Development and Filings
    - 10.1.1.4 Forecasts
  - 10.1.2 TechnoSphere Inhaled Insulin (MannKind Corporation)
    - 10.1.2.1 Efficacy
    - 10.1.2.2 Safety
    - 10.1.2.3 Development and filings
    - 10.1.2.4 Forecasts
  - 10.1.3 AIR inhaled Insulin (Eli Lilly/Alkermes)
    - 10.1.3.1 Efficacy
    - 10.1.3.2 Safety
    - 10.1.3.3 Development and Filings
    - 10.1.3.4 Forecasts
  - 10.1.4 Other Pulmonary Insulin in Clinical Development
    - 10.1.4.1 Kos Pharmaceuticals
    - 10.1.4.2 QDose Pharmaceuticals
    - 10.1.4.3 Coremed Inc
- 10.2 Oral Insulin
  - 10.2.1 Oral-Lyn/Oralgen/Oralin (Generex)
  - 10.2.2 Oral Insulin (Hubei Huagong Biochemical Engineering)
- 10.3 Transoral Patch Insulin
  - 10.3.1 ALT 1391 (Altea Therapeutics)
  - 10.3.2 Transoral Insulin Patch (Noven Pharmaceuticals)
- 10.4 Sales Forecasts of New Insulin Formulations
11 Alternative Approaches to the Treatment of Diabetes
- 11.1 The Sodium-Dependent Glucose Transporter Inhibitors (SGLT inhibitors)
  - 11.1.1 The SGLT 1 inhibitors
  - 11.1.2 The SGLT 2 inhibitors
- 11.2 Protein Tyrosine Phosphatase Inhibitors (PTP ase)
- 11.3 The Glycogenolysis/Gluconeogenesis Modulators
  - 11.3.1 Glycogen phosphorylase inhibitors
  - 11.3.2 Fructose-biphosphatase inhibitors
  - 11.3.3 Glucagon receptor antagonists
  - 11.3.4 Glucokinase activators
- 11.4 Sales Forecasts of Alterative Diabetes Therapies
12 Treatments for Diabetes Complications
- 12.1 Diabetic Retinopathy
- 12.2 Diabetic Nephropathy
- 12.3 Diabetic Neuropathy
- 12.4 Current Treatments for Diabetic Complications
  - 12.4.1 Antihypertensive use in Diabetic Nephropathy
  - 12.4.2 Anticonvulsant use in Diabetic Neuropathy
  - 12.4.3 Antidepressant use in Diabetic Neuropathy
- 12.5 New Treatments for Diabetic Complications
  - 12.5.1 Arxxant (Eli Lilly)
    - 12.5.1.1 Efficacy
    - 12.5.1.2 Safety
    - 12.5.1.3 Development & Filing
    - 12.5.1.4 Forecasts
  - 12.5.2 Avosentan (Speedel)
    - 12.5.2.1 Efficacy
    - 12.5.2.2 Safety
    - 12.5.2.3 Development and Filing
    - 12.5.2.4 Forecasts
  - 12.5.3 Candesartan (Takeda/AstraZeneca)
  - 12.5.4 Fidarestat (Sankyo/Sanwa Kagaku Kenkyusho)
  - 12.5.5 Neurodex (Avanir)
    - 12.5.5.1 Efficacy
    - 12.5.5.2 Safety
    - 12.5.5.3 Development and filing
  - 12.5.6 Perzinfotel (Wyeth)
  - 12.5.7 Ranirestat (Dainippon Sumitomo/Eisai)
  - 12.5.8 Rasilez (Novartis/Speedel)
    - 12.5.8.1 Efficacy
    - 12.5.8.2 Safety
    - 12.5.8.3 Development & Filing
    - 12.5.8.4 Forecasts
  - 12.5.9 Sulonex (Keryx)
    - 12.5.9.1 Efficacy
    - 12.5.9.2 Safety
    - 12.5.9.3 Development & Filing
    - 12.5.9.4 Sales forecasts and Assumptions
  - 12.5.10 Sativex (GW Pharma)
  - 12.5.11 TAK 428 (Takeda)
  - 12.5.12 V3381 (Vernalis)
- 12.6 Drugs in Early Phase Clinical Development For Diabetic Complications
  - 12.6.1 ABT-894 (Abbott)
  - 12.6.2 AV-101 (VistaGen)
  - 12.6.3 CNS 5161 (CeNeS)
  - 12.6.4 SB-509 (Sangamo BioSciences)
- 12.7 Sales forecasts of Key Drugs to Treat Diabetic Complications
13 The Diabetes Diagnostic Market
- 13.1 The Glucose Monitoring Market
  - 13.1.1 Self-Monitoring of Blood Glucose
  - 13.1.2 Glucose Meters
  - 13.1.3 Non-Invasive Testing
  - 13.1.4 Continuous Blood Glucose Monitoring
- 13.2 The Insulin Delivery Market
14 Company Profiles
- Abbott Laboratories
- Amylin Pharmaceuticals Inc
- Bristol-Myers Squibb
- Bayer Group
- Eli Lilly and Company
- F. Hoffman-La Roche Ltd
- GlaxoSmithKline plc
- Keryx Biopharmaceuticals
- LifeScan Inc
- Medtronic Inc.
- Merck & Co.Inc
- Novartis Pharmaceuticals
- Novo Nordisk A/S
- Pfizer
- Sanofi-Aventis
- Takeda Pharmaceutical Company Ltd
- Glossary of Terms
List of Tables
- Table 2.1 Global Sales Forecasts of Anti Diabetic Products 2005A-2012E
- Table 2.2 Major Players Within the Diabetes Market (2005)
- Table 2.3 Historical Sales of Leading Insulin Brands* (2001-2005)
- Table 2.4 Historical Sales of Leading Non-Insulin Brands* (2001-2005)
- Table 2.5 Major Players within the Diabetes Market (2012E)
- Table 3.1 Criteria for the Diagnosis of Diabetes
- Table 3.2 Criteria for the Diagnosis of Pre-Diabetes
- Table 4.1 Estimated Number of People with Diabetes Globally (2005A & 2030E)
- Table 7.1 Treatment Options for Diabetics
- Table 7.2 Classes of OADs
- Table 7.3 Approved SUs
- Table 7.4 Advantages and Disadvantages of SUs
- Table 7.5 Sales Forecasts of Leading SUs 2005A - 2012E
- Table 7.6 Approved MGs
- Table 7.7 Advantages and Disadvantages of MGs
- Table 7.8 Sales Forecasts of Leading MGs 2005A - 2012E
- Table 7.9 Approved BGs
- Table 7.10 Advantages and Disadvantages of BGs
- Table 7.11 Sales Forecasts of Leading BGs 2005A - 2012E
- Table 7.12 Approved TZDs
- Table 7.13 Advantages and Disadvantages of TZDs
- Table 7.14 Approved Combination Therapies
- Table 7.15 Advantages of Combination Therapies
- Table 7.16 Sales Forecasts of Leading TZDs Therapies 2005A - 2012E
- Table 7.17 Approved Alpha-glucosidase inhibitors (Alpha Gis)
- Table 7.18 Advantages and Disadvantages of Alpha GIs
- Table 7.19 Sales Forecasts of Leading Alpha Gis 2005A-2012E
- Table 7.20 Advantages and Disadvantages of Byetta
- Table 7.21 Sales Forecasts of Approved Insulin Secretion Promoting Agents 2005A - 2012E
- Table 7.22 Advantages and Disadvantages of Symlin
- Table 7.23 Sales Forecasts of Approved Amylinomimetics 2005A - 2012E
- Table 7.24 Sales Forecasts of Approved Non-Insulin Drugs 2005A - 2012E
- Table 8.1 Types of Injectable Insulin
- Table 8.2 Pharmokinetic Profile of Types of Injectable Insulin
- Table 8.3 Injectable Short Acting Insulin & Rapid Acting Insulin Analogues
- Table 8.4 Advantages and Disadvantages of Rapid Acting Insulin Analogues
- Table 8.5 Sales Forecasts of Rapid Acting Analogues and Short Acting Insulin (2005A - 2012E)
- Table 8.6 Intermediate and Long Acting Insulin
- Table 8.7 Advantages and Disadvantages of Intermediate-Acting Insulin
- Table 8.8 Sales Forecasts of Intermediate Human Insulin 2005A - 2012E
- Table 8.9 Approved Pre-Mixes
- Table 8.10 Sales Forecasts of Pre-Mixed Insulin 2005A - 2012E
- Table 8.11 Advantages and Disadvantages of Long-Acting Insulin
- Table 8.12 Sales Forecasts of Long-Acting Insulin's 2005A - 2012E
- Table 8.13 Pharmokinetic Profile of Pulmonary Insulin
- Table 8.14 Advantages and Disadvantages of Pulmonary Insulin
- Table 8.15 Sales Forecasts of Pulmonary Insulin 2005A - 2012E
- Table 8.16 Sales Forecasts of Approved Insulin Drugs 2005A - 2012E
- Table 9.1 Anti-Diabetes Agents in Late-Stage Clinical Development
- Table 9.2 Risks Raised by HbA1c 1% Change
- Table 9.3 Insulin Secretion Promoting Drugs in Clinical Development
- Table 9.4 Advantages and Disadvantages of GLP-1Analogues and DPP IV Inhibitors
- Table 9.5 Sales Forecasts of New Insulin Secretion Promoting Agents 2006E - 2010E
- Table 9.6 New Insulin Sensitizing Drugs in Clinical Development
- Table 9.7 PPAR Isoforms
- Table 9.8 Advantages and Disadvantages of Dual Acting PPAR Agonists and PPAR Pan Agonists
- Table 9.9 Sales Forecasts of New Insulin Sensitizing Agents 2006E - 2012E
- Table 10.1 New Formulations of Insulin in Clinical Development
- Table 10.2 Sales Forecasts of New Insulin Formulations 2006E - 2012E
- Table 11.1 SGLT Isoforms
- Table 12.1 Current Approved Treatments for Diabetic Complications
- Table 12.2 New Treatments in Development for Diabetic Complications
- Table 12.3 Sales Forecasts for New Treatments for Diabetic Complications (2006E-2012E)
- Table 13.1 Glucose Monitoring Device Manufacturers and Products
- Table 13.2 Key Features of Some Leading Glucose Meters
- Table 13.4 Insulin Pump Suppliers
- Table 13.3 Developmental Continuous Monitoring Devices
List of Figures
- Figure 2.1 Diabetes Market US$15bn - Regional Sales Split (2005)
- Figure 2.2 Diabetes Market US$15bn - Drugs Sales Split (2005)
- Figure 2.3 Insulin Market US$7.2 billion - Drug Class Sales Split (2005)
- Figure 2.4 Insulin Market US$7.2 billion-Regional Sales Split (2005)
- Figure 2.5 Non-Insulin Market US$7.5 billion - Drug Class Split (2005)
- Figure 2.6 Non-Insulin Market US$7.5 billion - Regional Sales Split (2005)
- Figure 2.7 Diabetic Neuropathy Market US$1.0 billion - Drugs Sales Split (2005)
- Figure 2.8 Glucose Monitoring Market US$ 6.1bn - Regional Sales Split (2005)
- Figure 2.9 Key Players in the Diabetes Market (2005)
- Figure 2.10 Key Players in the Insulin Market by Revenue (2005)
- Figure 2.11 Key Players in the Non-Insulin Market by Revenues (2005)
- Figure 2.12 Key Players in the Diabetic Neuropathy Market (2005)
- Figure 2.13 Key Players in the Glucose Monitoring Market US$6bn (2005)
- Figure 3.1 Glycosylated hemoglobin levels versus blood glucose
- Figure 7.1 Schematic of Glycaemic Control in Non-Diabetics and Diabetics
- Figure 7.2 Treatment Algorithm for Type2 Diabetics
- Figure 7.3 Treatment Mechanisms for Type 2 Diabetes Drugs
- Figure 7.4 Secondary Endpoint for PROactive Study
- Figure 7.5 The Effect of Oral Combination Therapies on Hb1Ac Levels
- Figure 7.6 Schematic Depicting GLP-1 Mechanism of Action
- Figure 7.7 Schematic Depicting Amylin's Mechanism of Action
- Figure 8.1 Profile of Short-Acting and Rapid Acting Insulin
- Figure 8.2 Profile of Intermediate-Acting Insulin Given Once and Twice Daily
- Figure 8.3 Profile of Pre-Mixed Insulin
- Figure 8.4 Profile of Long-Acting Insulin
- Figure 8.5 The Effect of Pulmonary Insulin Versus SC Insulin on Hb1AC levels
- Figure 9.1 Liraglutide Molecular Structure
- Figure 9.2 Denagliptin ('093) Phase 2a Data
- Figure 13.1 Schematic of Medtronic's MiniMed Paradigm REAL-Time System